Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published May 18, 2023
DOI: https://doi.org/10.22551/2023.39.1002.10241
Andrada Larisa Deac Raluca Maria Pop Cristina Florina Crisan Claudia Cristina Burz Anca Dana Buzoianu

Abstract

Fluoropyrimidines remain some of the most used chemotherapeutics, despite the appearance in the therapeutic arsenal of targeted therapy and immunotherapy. Fluropyrimidines related cardiotoxicity is an undesirable adverse event and affects almost 20% of patients. The mechanisms of fluoropyrimidine toxicity are closely related to deficient allelic variants of DPYD, but considering the low penetrance and interindividual variability, not all adverse reactions are explained by their presence. In this case, we report a patient with recurrent fluoropyrimidine toxicity without a deficient allelic variant and how this case was managed by the oncologist and cardiologist, considering the need to use fluoropyrimidine in the treatment.

##plugins.themes.bootstrap3.article.details##

Keywords

DPYD, colon cancer, fluoropyrimidines, cardiotoxicity, mutation testing

References
1. Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. PMID: 27589829.
2. Deac AL, Burz CC, Bocşe HF, Bocşan IC, Buzoianu AD. A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment. Med Pharm Rep. 2020;93(3):223-230. doi: 10.15386/mpr-1564. PMID: 32832886; PMCID: PMC7418836.
3. Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardio-Oncology. 2019;5:13. Doi: 10.1186/s40959-019-0048-3. PMID: 32154019; PMCID: PMC7048125.
4. Quaranta S, Thomas F. Pharmacogenetics of anti-cancer drugs: state of the art and implementation – recommendations of the French National Network of Pharmacogenetics. Therapie. 2017;72(2):205-215. 10.1016/j.therap.2017.01.005. PMID: 28262261
5. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939-950. doi: 10.1016/j.ejca.2003.12.004. PMID: 15093568.
6. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639-1650. doi: 10.1016/S1470-2045(15)00286-7. PMID: 26603945.
7. Boisdron-Celle M, Capitain O, Faroux R, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach. Semin Oncol. 2017;44(1):13-23. doi: 10.1053/j.seminoncol.2017.02.008. PMID: 28395758.
8. Kanduri J, More LA, Godishala A, Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol Clin. 2019;37(4):399-405. doi: 10.1016/j.ccl.2019.07.004. PMID: 31587781.
9. Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. doi: 10.1177/1758835918780140. PMID: 29977352; PMCID: PMC6024329.
10. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974-984. doi: 10.1016/j.ctrv.2013.03.005. PMID: 23582737.
11. Karabay CY, Gecmen C, Aung SM, et al. Is 5-fluorouracil-induced vasospasm a Kounis syndrome? A diagnostic challenge. Perfusion. 2011;26(6):542-545. doi: 10.1177/0267659111410347. PMID: 21628340.
12. Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11(1):46-9. doi: 10.1177/107327480401100207. PMID: 14749623.
13. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53(13):3028-3033. PMID: 8391384.
14. Thyss A, Gaspard MH, Marsault R, et al. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol. 1992;3(1):88. doi: 10.1093/oxfordjournals.annonc.a058084. PMID: 1606078.
15. Clasen SC, Ky B, O'Quinn R, et al. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970-979. doi: 10.21037/jgo.2017.09.07. PMID: 29299356; PMCID: PMC5750187.
16. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75-82. doi: 10.1007/s00432-007-0250-9. PMID: 17636329.
17. Ison G, Beaver JA, McGuinn WD Jr, et al. FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs. Clin Cancer Res. 2016;22(18):4545-9. doi: 10.1158/1078-0432.CCR-16-0638. PMID: 27401247.
How to Cite
Deac, A. L., Pop, R. M., Crisan, C. F., Burz, C. C., & Buzoianu, A. D. (2023). Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations. Archive of Clinical Cases, 10(2), Arch Clin Cases. 2023;10(2):55-60. https://doi.org/10.22551/2023.39.1002.10241
Issue
Vol. 10 No. 2 (2023)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Deac, A. L., Pop, R. M., Crisan, C. F., Burz, C. C., & Buzoianu, A. D. (2023). Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations. Archive of Clinical Cases, 10(2), Arch Clin Cases. 2023;10(2):55-60. https://doi.org/10.22551/2023.39.1002.10241